S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
NASDAQ:CRIS

Curis (CRIS) Stock Price, News & Analysis

$10.41
-0.46 (-4.23%)
(As of 09:55 AM ET)
Today's Range
$10.41
$10.95
50-Day Range
$8.49
$12.24
52-Week Range
$3.80
$20.00
Volume
3,752 shs
Average Volume
33,485 shs
Market Capitalization
$61.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.33

Curis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
243.5% Upside
$37.33 Price Target
Short Interest
Healthy
0.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.04mentions of Curis in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.92) to ($4.88) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.99 out of 5 stars

Medical Sector

392nd out of 939 stocks

Biological Products, Except Diagnostic Industry

61st out of 157 stocks

CRIS stock logo

About Curis Stock (NASDAQ:CRIS)

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

CRIS Stock Price History

CRIS Stock News Headlines

the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Curis Inc Q4 sales decline
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Curis Provides Fourth Quarter 2023 Business Update
Curis's Earnings: A Preview
Curis Announces Three Presentations at ASH
Curis Inc CRIS
See More Headlines
Receive CRIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CRIS
CUSIP
23126910
Employees
49
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$37.33
High Stock Price Target
$60.00
Low Stock Price Target
$26.00
Potential Upside/Downside
+243.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-47,410,000.00
Net Margins
-473.04%
Pretax Margin
-473.04%

Debt

Sales & Book Value

Annual Sales
$10.02 million
Book Value
$3.34 per share

Miscellaneous

Free Float
5,610,000
Market Cap
$64.02 million
Optionable
No Data
Beta
3.76

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

CRIS Stock Analysis - Frequently Asked Questions

Should I buy or sell Curis stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRIS shares.
View CRIS analyst ratings
or view top-rated stocks.

What is Curis' stock price target for 2024?

3 Wall Street analysts have issued 12-month price objectives for Curis' stock. Their CRIS share price targets range from $26.00 to $60.00. On average, they predict the company's stock price to reach $37.33 in the next twelve months. This suggests a possible upside of 243.5% from the stock's current price.
View analysts price targets for CRIS
or view top-rated stocks among Wall Street analysts.

How have CRIS shares performed in 2024?

Curis' stock was trading at $12.75 at the beginning of the year. Since then, CRIS shares have decreased by 14.7% and is now trading at $10.87.
View the best growth stocks for 2024 here
.

Are investors shorting Curis?

Curis saw a decline in short interest in March. As of March 15th, there was short interest totaling 47,900 shares, a decline of 14.5% from the February 29th total of 56,000 shares. Based on an average daily volume of 35,000 shares, the short-interest ratio is currently 1.4 days. Approximately 0.8% of the shares of the stock are short sold.
View Curis' Short Interest
.

When is Curis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CRIS earnings forecast
.

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) released its quarterly earnings data on Thursday, February, 8th. The biotechnology company reported ($2.03) EPS for the quarter, missing analysts' consensus estimates of ($1.91) by $0.12. The biotechnology company had revenue of $2.70 million for the quarter, compared to analysts' expectations of $2.95 million. Curis had a negative net margin of 473.04% and a negative trailing twelve-month return on equity of 169.22%. During the same quarter in the previous year, the firm earned ($2.40) earnings per share.

When did Curis' stock split?

Curis's stock reverse split before market open on Friday, September 29th 2023. The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Curis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK).

Who are Curis' major shareholders?

Curis' stock is owned by many different retail and institutional investors. Top institutional investors include Kingdon Capital Management L.L.C. (4.82%), Vanguard Group Inc. (3.54%), Vanguard Group Inc. (3.54%), Arnhold LLC (0.28%), Northern Trust Corp (0.27%) and a16z Perennial Management L.P. (0.11%).
View institutional ownership trends
.

How do I buy shares of Curis?

Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRIS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners